anonymous
Guest
anonymous
Guest
Simple math. The layoffs are due to the incredibly difficult gross to net for the primary care portfolio. Farxiga is SO heavily rebated and discounted. On top of that, we buy down people’s commercial copay with cards/vouchers. I would bet we ‘make’ less than $.25 for every $1.00 sold. That is not sustainable at all. Hence, why do we need to continue paying a bloated sales force? And the majority of those reps are barely able to see any of their targets due to pandemic.
future of pharma is in higher margin disease states; specialty, oncology, etc. while primary care products won’t go away, the sales model will definitely adjust to meet the business realities.
future of pharma is in higher margin disease states; specialty, oncology, etc. while primary care products won’t go away, the sales model will definitely adjust to meet the business realities.